Publication:
Aggressive Form of Multiple Sclerosis Can Be Predicted Early After Disease Onset

Simple item page
dc.contributor.authorMalpas, C. B.
dc.contributor.authorManouchehrinia, A.
dc.contributor.authorSharmin, S.
dc.contributor.authorRoos, I.
dc.contributor.authorHorakova, D.
dc.contributor.authorHavrdova, E. K.
dc.contributor.authorIuliano, G.
dc.contributor.authorIDFerraro, Diana/0000-0003-4818-3806
dc.contributor.authorIDTurkoglu, Recai/0000-0001-9724-851X
dc.contributor.authorIDAltintas, Ayse/0000-0002-8524-5087
dc.contributor.authorIDMcCombe, Pamela/0000-0003-2704-8517
dc.date.accessioned2020-06-21T12:26:01Z
dc.date.available2020-06-21T12:26:01Z
dc.date.issued2019
dc.departmentOMÜen_US
dc.department-temp[Malpas, C. B. -- Sharmin, S. -- Roos, I. -- Kalincik, T.] Univ Melbourne, Dept Med, CORe Unit, Melbourne, Vic, Australia -- [Manouchehrinia, A. -- Olsson, T. -- Hillert, J.] Karolinska Inst, Dept Clin Neurosci, Stockholm, Swedenen_US
dc.description35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS -- SEP 11-13, 2019 -- Stockholm, SWEDENen_US
dc.description.abstract…en_US
dc.description.sponsorshipEuropean Comm Treatment & Res Multiple Sclerosis, Congrex Switzerland Ltden_US
dc.description.sponsorshipCharles University in Prague [PRVOUK-P26/LF1/4]; Czech Minsitry of Education [PROGRES Q27/LF1]; Czech Ministry of HealthMinistry of Health, Czech Republic [NT13237-4/2012]; Czech Ministry of EducationMinistry of Education, Youth & Sports - Czech Republic [PROGRES Q27/LF1]; BiogenBiogenen_US
dc.description.sponsorshipDana Horakova received speaker honoraria and consulting fees from Biogen, Merck, Teva and Novartis, as well as support for research activities from Biogen and research grants from Charles University in Prague [PRVOUK-P26/LF1/4], Czech Minsitry of Education [PROGRES Q27/LF1] and Czech Ministry of Health [NT13237-4/2012].; Eva Kubala Havrdova received speaker honoraria and consultant fees from Actelion, Biogen, Celgene, Merck, Novartis, Roche, Sanofi and Teva, and support for research activities from Czech Ministry of Education [project Progres Q27/LF1].en_US
dc.identifier.endpage607en_US
dc.identifier.issn1352-4585
dc.identifier.issn1477-0970
dc.identifier.startpage605en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12712/10628
dc.identifier.volume25en_US
dc.identifier.wosWOS:000485303102302
dc.language.isoenen_US
dc.publisherSage Publications Ltden_US
dc.relation.journalMultiple Sclerosis Journalen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleAggressive Form of Multiple Sclerosis Can Be Predicted Early After Disease Onseten_US
dc.typeConference Objecten_US
dspace.entity.typePublication

Files

Collections

WoS İndeksli Yayınlar Koleksiyonu